Related: Explore Transparent GLP-1 Pricing You may qualify for semaglutide or tirzepatide if your weight is affecting your health, function, or quality of life
Proper dosing not only enhances the effectiveness of your treatment but also minimizes the risk of side effects
133 , e167337 (2023)

Medications licensed for type 2 diabetes include: Exenatide (Byetta, Bydureon): Available as twice-daily injections or once-weekly extended-release formulation Liraglutide (Victoza): Administered as a once-daily subcutaneous injection at doses up to 1.8 mg for diabetes Dulaglutide (Trulicity): Once-weekly injection with pre-filled pen devices Semaglutide (Ozempic): Once-weekly injection for diabetes management Oral semaglutide (Rybelsus): The first oral GLP-1 agonist, taken daily For weight management specifically, two formulations have received UK marketing authorisation: Liraglutide 3.0 mg (Saxenda): Licensed for weight management in adults with a BMI 30 kg/m, or 27 kg/m with weight-related comorbidities Semaglutide 2.4 mg (Wegovy): Once-weekly injection approved for chronic weight management under similar BMI criteria It is crucial to understand that whilst these medications demonstrate efficacy in promoting weight loss, they are not specifically indicated for leptin resistance

Clinical data suggests that GIP co-activation with GLP-1 may also reduce nausea rates compared to GLP-1 stimulation alone, which could explain why Retatrutide and Tirzepatide cause less nausea than Semaglutide despite being more potent compounds
While our anti-aging peptides gradually smooth surface-level lines by boosting collagen, wrinkle relaxers like Botox work by limiting specific muscle movements